More than 40% of healthy mothers recruited for a study testing fecal transplantation for babies born by cesarean section tested positive for potentially harmful pathogens, Finnish researchers reported.
The study, presented at the European Congress of Clinical Microbiology & Infectious Diseases, is the latest to examine fecal transplant therapy, which has been shown to prevent recurrent Clostridioides difficile infection in adults. The FDA in December approved a fecal microbiota product for the first time to treat recurrent C. difficile.
In their abstract, Otto Helve, MD, PhD, a pediatric